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Abstract
Integrin inhibitors based on the tripeptide sequence Arg–Gly–Asp (RGD) are potential therapeutics for the treatment of idiopathic
pulmonary fibrosis (IPF). Herein, we describe an expeditious three-step synthetic sequence of Horner–Wadsworth–Emmons olefi-
nation, diimide reduction, and global deprotection to synthesise cores for these compounds in high yields (63–83% over 3 steps)
with no need for chromatography. Key to this transformation is the phosphoramidate protecting group, which is stable to metala-
tion steps.
Introduction
Tetrahydronaphthyridines are prominent in peptidomimetic
pharmaceuticals as arginine mimetics and they are widely used
in Arg–Gly–Asp (RGD) peptide mimetics such as αv integrin
inhibitors [1]. Tetrahydronaphthyridines represent less basic but
more permeable alternatives to arginine (pKa ≈ 7 versus 13.8)
[1] replicating the side-on salt-bridge binding interaction made
between the guanidinium functionality of arginine and an
aspartic acid residue in the protein. Consequently, this moiety
has been used in various integrin inhibitors (Figure 1) [2-8].
Current routes to install tetrahydronaphthyridines predominant-
ly revolve around late-stage hydrogenation of fully aromatic
1,8-naphthyridine derivatives 3, usually prepared via an acid or
base-catalysed Friedländer reaction between 2-aminonicotin-
aldehyde (1) and the corresponding ketone 2 (Scheme 1). Both
reactions employ harsh conditions with limited functional group
tolerance and limited regiochemical control, which presents
considerable purification issues during large-scale synthesis
[8-10]. More recently, catalytic methodologies for the asym-
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Figure 1: The Arg–Gly–Asp tripeptide sequence and examples of tetrahydro-1,8-naphthyridine-containing integrin inhibitors.
Scheme 1: Commonly used synthetic routes to tetrahydro-1,8-naphthyridine moieties by hydrogenation of saturated naphthyridines 3.
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Scheme 2: Previous synthetic route to fluoropyrrolidine 6 utilising a Wittig reaction and the novel, higher yielding route using a
Horner–Wadsworth–Emmons reaction.
metric hydrogenation of 1,8-naphythyridines have been re-
ported [11,12].
Recently, GlaxoSmithKline disclosed a route to a fluoropyrroli-
dine 6 using a Wittig reaction between phosphonium salt 4
and aldehyde 5 [2]. The synthesis of phosphonium salt 4
(itself requiring 6 steps including partial saturation of a 1,8-
naphthyridine moiety) and the formation of the triphenylphos-
phine oxide byproduct in the Wittig step presented complica-
tions on both gram and kilogram scales. Herein, we report a
novel synthetic sequence to tetrahydro-1,8-naphthyridines using
a Horner–Wadsworth–Emmons reaction using diphosphory-
lated compound 7, proceeding in high yields and high purities
without the need for chromatographic purification (Scheme 2).
Results and Discussion
Based on applications of phosphonates derived from 2-methyl-
pyridine and 2-methlylquinoline derivatives in Horner–Wads-
worth–Emmons olefinations [13-15], it was proposed that simi-
lar a methodology could be applied to 7-methyl-1,2,3,4-tetra-
hydro-1,8-naphthyridine analogues. The investigation initially
began using commercially available N-Boc-protected tetra-
hydro-1,8-naphthyridine 8 [16]. Upon deprotonation and
quenching with diethyl chlorophosphate, migration of the Boc
group from the nitrogen atom to the exocyclic methyl group
was observed, affording phosphoramidate 9 in low yield, indi-
cating good leaving group ability of the stabilised tetrahydro-
naphthyridine anion. No formation of phosphonate 10 was
detected (Scheme 3).
It was proposed that a deprotonation of 7-methyl-1,2,3,4-tetra-
hydro-1,8-naphthyridine (11) with two equivalents of sec-BuLi
would afford phosphonate 12 upon quenching with diethyl
chlorophosphate via formation of the dianion. This could then
be used in a subsequent Horner–Wadsworth–Emmons reaction
to construct the carbon skeleton of amine 6. Upon the addition
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Scheme 3: Synthesis of phosphoramidate 9 from tetrahydro-1,8-naphthyridine 8. Conditions: s-BuLi (3 equiv), diethyl chlorophosphate (1.1 equiv),
THF, −42 °C, 30 min, 14% yield.
Scheme 4: Mono- and diphosphorylation of tetrahydro-1,8-naphthyridine 11. Conditions: (i) s-BuLi (2 equiv), diethyl chlorophosphate (1 equiv), THF,
−78 °C, 4 h, 44% yield; (ii) s-BuLi (2 equiv), diethyl chlorophosphate (2 equiv), THF, −78 °C, 4 h, 33% yield.
of a single equivalent of diethyl chlorophosphate, phosphor-
amidate 13 was obtained exclusively at both −42 and −78 °C.
The addition of two equivalents of the chlorophosphate yielded
diphosphorylated compound 7, albeit in poor yield (Scheme 4).
The deprotonation of phosphonate 7 and subsequent reaction
with aldehyde 5, formed in situ by oxidation of alcohol 14 using
T3P® [17], yielded olefin 15 in 93% yield as a 94:5 mixture of
stereoisomers – presumably E/Z, although this is not conclusive
from the 1H NMR spectrum. Based on LC–MS and 1H NMR
spectroscopy observations, it is believed that aldehyde 5 exists
predominantly as the corresponding hydrate and an excess of
base (6 equiv) was required to overcome stalling of the olefina-
tion process. Reduction to compound 16 using benzenesulfonyl
hydrazide (generating diimide in situ) proceeded in 80% yield
and was followed by single-pot carbamate and phosphonate
deprotection to afford arginine mimetic 6 in 86% yield. This
represents a 64% overall yield which was increased to 68%
when no column chromatography was undertaken between
transformations, with no loss of purity (Scheme 5).
Olefin reduction and Cbz deprotection could not be performed
simultaneously by palladium-catalysed hydrogenation as this
resulted in defluorination, presumably via a Tsuji–Trost-like
elimination of the allylic fluoride [18,19]. This sequence repre-
sents a marked improvement from the Wittig-including route,
lowering the number of synthetic steps and increasing the
overall yield [2]. Furthermore, no problematic byproducts are
formed, and good purity is obtained without the use of any
chromatography, which is ideal for large-scale processes.
Optimisation of the synthesis of phosphor-
amidate 13 and phosphonate 7
Having been shown to be a feasible intermediate, attention
turned to improving the synthesis of bisphosphonate 7 via a
two-step process, exploiting the base stability of the phosphor-
amidate protecting group. A variety of bases were trialed at
0 °C for the initial N-phosphorylation, with 10 minutes allowed
for complete deprotonation to occur (Table 1).
Only minimal phosphorylation was observed when using potas-
sium tert-butoxide (Table 1, entry 1). This may be due the
disparity in the pKa between the base and tetrahydro-1,8-naph-
thyridine (based on 2-aminopyridine, the pKa of the saturated
ring nitrogen is expected to be ≈28) [20]. Similarly, nitrogen-
centred bases (Table 1, entries 2 and 3) gave moderate conver-
sions to phosphoramidate 13 due to a close match of the pKa of
tetrahydronaphthyridine 11 and the pKaH of the base; s-BuLi
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Scheme 5: Synthesis of amine 6 from phosphonate 7 and aldehyde 5. Conditions: (i) T3P® (50% w/w in DCM, 3 equiv), DMSO (3 equiv), DIPEA
(2.5 equiv), DCM, 0 °C, 1 h; (ii) KOt-Bu (6 equiv), THF, 0 °C, 70 min, 93% yield over two steps (relative to phosphonate 7); (iii) PhSO2NHNH2
(3 equiv), K2CO3 (4 equiv), DMF, 100 °C, 30 min, 80% yield; (iv) 7.4 M HCl, 100 °C, 1.5 h, 86% yield.
Table 1: Bases surveyed for the formation of phosphoramidate 13.a
Entry Base Amount of
phosphoramidate
13/LC–MS a/a%
1 KOt-Bu (1 M in THF) 4
2 LiHMDS (1 M in THF) 58
3 LDA (2 M inhexanes/benzene) 58
4 s-BuLi (1.4 M incyclohexane) 65
5 iPrMgCl (2 M in THF) 88
aReactions performed on a 0.7 mmol scale of compound 11.
also gave reasonable conversion to the product (Table 1, entry
4) albeit contaminated with some impurities. This could likely
be attributed to the thermal instability of the base and/or lithi-
ated tetrahydronaphthyridine in THF at this temperature. The
use of iPrMgCl, a strong but room temperature-stable base,
gave the highest conversion to phosphoramidate 13. Further in-
vestigation into the use of iPrMgCl revealed that a quantitative
conversion was achieved at ambient temperature with a metala-
tion time of <1 minute. Pleasingly, premixing of tetrahydro-
naphthyridine 11 with diethyl chlorophosphate, followed by
dropwise addition of iPrMgCl gave a clean and total conver-
sion to phosphoramidate 13 as seen by LC–MS. When per-
formed on a multigram scale, a 94% yield of compound 13 was
obtained. The reaction also proceeded well (91% isolated yield)
in 2-MeTHF, which offers a preferred alternative if the reaction
is performed on a larger scale due to better partitioning with
water, stability, and sustainability of production [21]. Of the
bases trialled, only s-BuLi was efficient in promoting C-phos-
phorylation. Optimisation of the use of this base was then inves-
tigated further (Table 2).
An optimal deprotonation and phosphorylation was found to
occur when an excess (3 equiv) of base was used at −42 °C
(Table 2, entry 4), with a lithiation time of 20 min. The addi-
tion of TMEDA was detrimental to this conversion with a large
proportion of starting material 13 remaining (Table 2, entry 7).
No product was formed at higher temperatures (Table 2, entry
8), likely due to the instability of the C-lithiated species at
elevated temperatures as degradation was observed. It is
believed that the excess base loading is required to account for
the deprotonation of the more acidic phosphonate product 7
versus the starting material 13, and potential lithium sequestra-
tion by chelation between an oxygen atom of the phosphonate
and the nitrogen atom of the unsaturated ring. Monitoring of the
deprotonation followed by quenching with CD3OD by 1H and
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Table 2: Optimisation of the formation of phosphonate 7 using s-BuLi as a base.a
Entry T/°C s-BuLi/equiv Lithiation time/min Amount of phosphonate 7/LC–MS
a/a%
1 −78 1.5 90 53
2 −42 2.0 20 62
3 −42 2.5 20 81
4 −42 3.0 20 86
5 −42 3.5 20 67
6 −42 4.0 20 48
7 −42 3.0 (+ 3 equiv TMEDA) 20 59
8 0 2.0 10 0
aReactions were performed on a 4.6 mmol scale (entry 1), 0.5 mmol scale (entries 2–6), 0.3 mmol (entry 7), or 0.4 mmol scale (entry 8).
Scheme 7: Sequential diphosphorylation of tetrahydronaphthyridine 11. Conditions: (i) iPrMgCl (1.5 equiv), THF, then diethyl chlorophosphate
(1.2 equiv), 5 min, 94% yield; (ii) s-BuLi (3 equiv), THF, −42 °C, 20 min, then (EtO)2P(O)Cl (1.1 equiv), 20 min, 68% yield.
13C NMR spectroscopy indicated the formation of the monola-
belled compound 17 as the major product, demonstrating that
lithiation only occurs at a single position of compound 13
(Scheme 6).
Scheme 6: Monodeuteration of 13 as observed by 1H and 13C NMR.
Conditions: s-BuLi (3 equiv), THF, −42 °C, 20 min then CD3OD
(14 equiv), 5 min.
When performed on a multigram scale, phosphonate 7 was iso-
lated in 68% yield after purification by chromatography on
silica. This, combined with the formation of phosphoramidate
13 in 94% yield, represented a marked improvement to the
initial one-pot diphosphorylation (Scheme 7). Contrary to
reports using 2-methylquinolines, tandem phosphorylation and
olefination was not possible [15]. When a sequential diphospho-
rylation was attempted in a single pot, diphosphorylated com-
pound 7 was not observed, with phosphoramidate 13 account-
ing for the majority of product formed [22].
Reaction scope
The sequence of olefination, reduction, and deprotection was
tested on other arginine mimetics of varying amine structure,
constituting potential Arg–Gly components of Arg–Gly–Asp
integrin inhibitors (Table 3). Where the aldehyde was not com-
mercially available, N-Boc-protected alcohols were oxidised
using IBX in refluxing ethyl acetate and used crude. Olefina-
tion required only a modest excess of base (1.5–2.4 equiv) and
proceeded in <1 h. Sodium hydride was investigated as a
heterogeneous alternative to potassium tert-butoxide, although a
lower isolated yield of the final amine was obtained. All amines
were formed in high NMR and LC–MS purity without the need
for purification by column chromatography.
Pleasingly, the sequence proceeded in high yields (63–83%) for
all substrates with no chromatography required. Despite rela-
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Table 3: Cores synthesised by the sequence of olefination, reduction, and deprotection, and the corresponding starting alcohols and aldehydes.a
Entry Alcohol Aldehyde Product Yield
1
18 19
20
82%b
2
21 22
23
83%b
3 –
24
25
79%c
4 –
26
27
63%d
aConditions: b(i) IBX (3 equiv), EtOAc, reflux, 2.25–3 h; (ii) KOt-Bu (1.5–2.3 equiv), THF, 0 °C, 7–40 min; K2CO3 (4 equiv), PhSO2NHNH2 (3 equiv),
DMF, 100 °C, 70–80 min; (iv) 7.4 M HCl, 100 °C, 2 h; c(ii) KOt-Bu (1.8 equiv), THF, 0 °C, 5 min; (iii) K2CO3 (4 equiv), PhSO2NHNH2 (3 equiv), DMF,
100 °C, 75 min; (iv) 7.4 M HCl, 100 °C 3.5 h; d(ii) NaH (2.4 equiv), THF, 0 °C, 70 min; (iii) K2CO3 (4 equiv), PhSO2NHNH2 (3 equiv), DMF, 100 °C,
2 h; (iv) 7.4 M HCl, 100 °C, 2 h.
tively high yields, significant racemisation was seen in the syn-
thesis of piperidine 20 and pyrrolidine cores 23. Pyrrolidine 23
was obtained with an ee of only 30%, representing a significant
loss of enantiopurity. It is believed that racemisation occurred
during the olefination step, caused by a base mediated
keto–enol tautomerisation. It was proposed that the use of lithi-
um hydroxide would promote hydrate formation, mitigating
racemisation of the aldehyde. However, this was unsuccessful
as complete racemisation was observed, with olefination
requiring five days to complete. No olefination was seen using
DIPEA under refluxing conditions. As such, this sequence, as
currently performed, is suitable for substrates lacking an acidic
α-proton (fluoropyrrolidine core 6) or achiral aldehydes (azeti-
dine cores 25 and 27).
Furthermore,  key to success of  the Horner–Wads-
worth–Emmons olefination was premixing of the aldehyde and
phosphonate 7 prior to the addition of KOt-Bu. Upon deproton-
ation, phosphonate 7 (in the absence of aldehyde) underwent
dimerisation to olefin 28. While the exact mechanism is not
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Scheme 8: Possible mechanistic pathways for the formation of dimer 28. Conditions: KOt-Bu, THF, 1 h, 68% yield.
Scheme 9: Alkylation of phosphoramidate 13 by iodide 29 to afford compound 30 and byproducts alcohol 31 and dimer 32. Use of bromide 33 or
tosylate 34 afforded only compounds 31 and 32. Conditions: (i) s-BuLi (1.3 equiv), iodide 29, THF, −78 °C, 30 min; (ii) 7.4 M HCl, 100 °C, 3.5 h, 92%
yield.
known, it may involve a reactive carbene intermediate formed
by α-elimination of the phosphonate as described in previous
reports [23]. Alternatively, a base-promoted autoxidation of
phosphonate 7 in the presence of trace amounts of oxygen, fol-
lowed by olefination may be taking place (Scheme 8) [24-26].
The autoxidation of phosphonates under THF/potassium tert-
butoxide has been reported previously [27].
In order to circumvent racemisation of aldehyde 22 during the
Horner–Wadsworth–Emmons olefination, alkylation of phos-
phoramidate 13 was explored using commercially available
iodide 29. The formation of compound 30 proceeded in 21%
yield, with alcohol 31 and dimer 32 also formed in 20% and 5%
yield, respectively (Scheme 9). Indeed, when iodide 29 was
replaced with bromide 33 and tosylate 34 no formation of
compound 30 was observed, with alcohol 31 and dimer 32
accounting for the major products. Acidic deprotection of
phosphoramidate 30 afforded amine (R)-23 in 92% yield in
>99% ee, offering an alternative route to the Horner–Wads-
worth–Emmons-based approach.
The mechanism of the formation of alcohol 31 and dimer 32
was not fully explored although it is likely to occur via a radical
pathway. When iodide 29 was replaced by a superior oxidant in
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1,2-dibromoethane, formation of dimer 32 increased (17% iso-
lated yield). This supports the previously reported proposals
that dimerisation occurs via single-electron oxidation of the
2-picolyl anion by the halide/pseudohalide oxidant followed by
recombination of the resulting picolyl radical [28-30]. Whilst
trace oxygen may be involved, as indicated by the presence of
alcohol 31, no dimerisation or alcohol formation was seen in the
absence of a halide/pseudohalide-based oxidant, during C-phos-
phorylation or deuteration.
Conclusion
In conclusion, a novel method for the assembly of 7-alkyl-
1,2,3,4-tetrahydro-1,8-naphthyridine-based arginine mimetics
was developed. The synthesis of phosphonate 7 was optimised,
with a sequential diphosphorylation process using commercial-
ly available starting materials affording the desired compound
in 64% overall yield. A Horner–Wadsworth–Emmons/reduc-
tion/deprotection procedure was used to synthesise amines in
good yield requiring no chromatography, although racemisa-
tion was observed where chiral aldehydes possessed an
α-proton. This methodology utilised the underused base-stable
phosphoramidate protecting group, which was superior to the
more commonly applied Boc protecting group which was
unstable to the lithiation. This synthetic route replaces tradi-
tional Wittig and tandem alkylation/reduction methodologies,
which suffer from complications arising from troublesome by-
products and reaction selectivity. The new procedure proceeds
in a higher yield than previously obtained and may potentially
offer benefits in large-scale manufacture of integrin inhibitors
and other arginine peptidomimetics.
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